Protein language models and structure prediction for aging-related targets
The application of deep learning models (e.g., ESMFold, AlphaFold2) to predict the 3D structure and functional interactions of protein targets implicated in biological aging, such as sirtuins, telomerase, or senescence-associated secretory phenotypes.
This skill drastically accelerates the discovery and design of novel therapeutics (e.g., senolytics, caloric restriction mimetics) by enabling high-fidelity, in-silico target validation and ligand screening, reducing wet-lab costs and timelines. It directly impacts pipeline efficiency, patentability, and success rates in the competitive longevity biotech sector.
1Careers
1Categories
9.2 Avg Demand
15%
Avg AI Risk
How to Learn Protein language models and structure prediction for aging-related targets
1. **Molecular Biology of Aging**: Master core pathways (mTOR, AMPK, NAD+, sirtuins, telomere attrition). 2. **Structural Bioinformatics Fundamentals**: Learn PDB file format, Ramachandran plots, sequence alignment (BLAST), and homology modeling principles. 3. **Python & ML Basics**: Proficiency in Python, NumPy, Pandas, and a basic understanding of neural network architectures (CNNs, Transformers).
1. **Applying PLMs**: Use pre-trained models (ESM-2, ProtBERT) to extract sequence embeddings for aging-related protein families (e.g., Klotho, p16INK4a). 2. **Fine-tuning for Structure**: Take AlphaFold2/ESMFold codebases and fine-tune on curated datasets of aging-related protein complexes (e.g., SIRT1-NAD+). 3. **Common Pitfall**: Avoid overfitting on small, non-diverse datasets; validate predictions with experimental constraints (e.g., HDX-MS, cryo-EM density maps).
1. **De Novo Design & Dynamics**: Integrate molecular dynamics (GROMACS, OpenMM) with PLM predictions to simulate conformational changes in targets like lamin A in progeria. 2. **Multi-Target & Pathway Modeling**: Build systems biology models that incorporate predicted structures to simulate network effects of modulating aging hubs. 3. **Strategic Leadership**: Mentor wet-lab teams on interpreting computational predictions, design hybrid discovery workflows, and navigate IP landscapes around AI-derived structures.
Practice Projects
Beginner
Project
Predicting the Structure of a Known Aging-Related Mutant Protein
Scenario
Predict the structural impact of the Lamin A (LMNA) p.G608G (progeria) mutation using ESMFold.
How to Execute
1. Retrieve the wild-type LMNA sequence from UniProt (P02545). 2. Use the ESMFold API or local model to predict the wild-type structure. 3. Introduce the G608G (c.1824C>T) synonymous mutation known to alter splicing and introduce a 50-aa deletion; predict the structure of the truncated protein. 4. Visualize and compare the wild-type and mutant structures in PyMOL, focusing on the disruption of the central rod domain.
Intermediate
Project
Virtual Screening for Senolytic Candidates Targeting BCL-2 Family Proteins
Scenario
Identify potential small-molecule inhibitors of the anti-apoptotic protein BCL-W (BCL2L2), a target in senescent cell clearance.
How to Execute
1. Obtain the predicted (AlphaFold2) or experimental (PDB: 4LVT) structure of BCL-W. 2. Use the predicted structure to define the binding pocket via SiteMap or fpocket. 3. Run a virtual screen of a focused senolytic compound library (e.g., from ZINC15) using AutoDock Vina or Glide. 4. Rank and filter compounds based on binding affinity, drug-likeness (Lipinski's rules), and selectivity over other BCL-2 family members (e.g., BCL-2, MCL-1).
Advanced
Project
Engineering a Caloric Restriction Mimetic via Protein-Protein Interface Design
Scenario
Design a peptide or small protein that stabilizes the active conformation of AMP-activated protein kinase (AMPK) by mimicking its interaction with a upstream kinase like LKB1.
How to Execute
1. Model the full-length AMPK complex (α, β, γ subunits) and its interaction with LKB1 using AlphaFold-Multimer. 2. Identify key interfacial residues and design a stabilizing peptide using Rosetta's FlexPepDock or protein language model-guided design (e.g., ProteinMPNN). 3. Validate the design in-silico by predicting the stability (ΔΔG) of the complex. 4. Outline a proposed experimental pipeline: gene synthesis, expression in mammalian cells, and functional assays measuring AMPK activity (ACC phosphorylation) and downstream effects (autophagy induction).
AlphaFold2/ESMFold (local or ColabFold)OpenFold (PyTorch-based AF2)ESM-2/ProtTrans (PLMs)
Use AlphaFold2/ESMFold for high-accuracy monomer and complex structure prediction. OpenFold allows for custom training/fine-tuning. ESM-2 embeddings are the gold standard for feature extraction for downstream tasks like function prediction or stability analysis.
MD suites simulate protein dynamics and ligand binding stability. Docking tools screen virtual libraries against static or ensemble structures. Rosetta is used for de novo protein/peptide design and interface optimization, critical for target engagement.
UniProt/PDB provide sequences and experimental structures. AlphaFold DB offers pre-computed predictions. ZINC15/ChEMBL are libraries for virtual screening and activity data. Visualization tools are non-negotiable for analysis, presentation, and debugging.
Interview Questions
Answer Strategy
The interviewer is assessing your understanding of the computational-to-experimental validation bridge. Use a structured framework: **1. In-silico Validation** (compare confidence pLDDT scores, check for physical plausibility via Ramachandran analysis). **2. Targeted Experimental Validation** (propose HDX-MS to probe predicted dynamics, or design a focused set of mutants for functional assays). **3. Drug Discovery Utility** (evaluate the predicted pocket druggability using SiteMap, and suggest a small pilot virtual screen to see if docking poses are chemically reasonable).
Answer Strategy
This tests your ability to manage expectations and understand the limits of computational models. The core competency is **critical evaluation of AI outputs**. Sample response: 'AlphaFold2 is transformative for static structure prediction, but for drug discovery, we need more. It doesn't reliably model ligand binding, conformational ensembles, or post-translational modifications-common in aging pathways. We should use AF2 to prioritize and design experiments (e.g., for crystallography or cryo-EM of complexes), not replace them. The highest value comes from a tight computational-experimental feedback loop.'
Careers That Require Protein language models and structure prediction for aging-related targets